Last updated on August 2019

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchial Neoplasm | Lung Cancer | Lung Neoplasm
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

  1. Documentation of Disease
    1. Histologically or cytologically documented small cell lung cancer (SCLC)
    2. Limited-stage disease patients with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes
      • Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible
      • Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not are not eligible unless they have a negative thoracentesis
      • Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray are not eligible
    3. Measurable disease - Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as 2 cm with conventional techniques OR 1 cm by spiral CT scan
    4. Prior Treatment
    5. Patients may have received one and only one cycle of chemotherapy prior to enrolling on CALGB 30610, which must have included carboplatin or cisplatin and etoposide.
    6. If a patient has had one cycle of cisplatin or carboplatin/etoposide prior to registration, the patient must have had all of it prior to registration tests as outlined in the protocol and prior to starting their first cycle of chemotherapy.
    7. Additionally, these patients also must have met all of the eligibility criteria in the protocol prior to receiving the first cycle of chemotherapy.
    8. Registration to CALGB 30610 must take place within 14-21 days after the start of the non-protocol therapy.
    9. Failing to do all of the above will make the patient NOT eligible for CALGB 30610.
    10. No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for SCLC
    11. No prior mediastinal or thoracic radiotherapy
    12. Patients with complete surgical resection of disease are not eligible
    13. Age Requirement 18 years of age
    14. ECOG Performance Status 0-2
    15. Non-pregnant and non-nursing - No patients that are known to be pregnant or nursing
    16. Required Initial Laboratory Values
    17. Granulocytes 1,500/l
    18. Platelet count 100,000/l
    19. Total bilirubin 1.5 times upper limit of normal (ULN)
    20. AST (SGOT) 2.0 times ULN
    21. Serum creatinine 1.5 times ULN OR Calculated creatinine clearance 70 mL/min

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.